In the study, Larkin and colleagues tested whether biomarkers within the blood metabolome could detect cancers within a mixed population of patients referred from primary care with nonspecific symptoms. The researchers reported that an NMR-based metabolomic analysis correctly detected solid tumors and identified metastatic disease (including breast cancer) among patients with a 94% rate of accuracy.
Furthermore, the NMR-based technique analyzed levels of metabolites in the blood as biomarkers to distinguish different cancer states using magnetic fields and radio waves. Larkin and colleagues emphasized a need to confirm the results in a larger cohort of patients and evaluate the test's use in a wider clinical context.
Learn more about the presentation of metastatic breast cancer.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Rapid Review Quiz: New Diagnostic Tests - Medscape - Jun 13, 2022.